David Blum, a veteran GlaxoSmithKline executive, is joining BioDelivery Sciences International as its vice president for medical affairs and clinical research.
Blum was medical director in the neuroscience medical development department at GSK for the past six years. An MD, Blum is a neurologist. He earned his medical degree at the University of California at San Diego.
BDSI is developing a variety of pain relieving drugs, including one product currently in Phase III clinical trials.